Opportunistic infections in HIV: Difference between revisions

From IDWiki
(: links)
(: changed to table layout)
Line 34: Line 34:


== Prophylaxis regimens ==
== Prophylaxis regimens ==
{| class="wikitable"
! Infection !! Preferred !! Alternative
|-
| rowspan=4 | ''[[Pneumocystis jirovecii]]'' (CD4 <200)
| rowspan=4 | [[TMP-SMX]] 1 DS or SS PO daily
| [[TMP-SMX]] 1 DS PO three times weekly
|-
| [[Dapsone]] 100 mg PO daily or 50 mg PO BID
|-
| [[Pentamidine]] nebs 300 mg every month
|-
| [[Atovaquone]] 1500 mg PO daily
|-
| rowspan=4 | ''[[Toxoplasma gondii]]'' (CD4 <100 and IgG positive)
| rowspan=4 | [[TMP-SMX]] 1 DS PO daily
| [[TMP-SMX]] 1 DS PO three times weekly
|-
| [[TMP-SMX]] 1 SS PO daily
|-
| [[Dapsone]] 50 mg PO daily + pyrimethamine/leucovorin PO weekly
|-
| [[Atovaquone]] 1500 mg PO daily
|-
| rowspan=3 | ''[[Mycobacterium avium complex]]'' (CD4 <50)
| rowspan=3 | [[Azithromycin]] 1200 mg PO once weekly
| [[Clarithromycin]] 500 mg PO BID
|-
| [[Azithromycin]] 600 mg PO twice weekly
|-
| [[Rifabutin]], dose-adjusted to HIV meds
|-
| ''[[Histoplasma capsulatum]]'' (CD4 <150 and high risk)
| [[Itraconazole]] 200 mg PO once daily
|
|}


"High risk" for ''Histoplasma'' includes occupational exposure or residence in a community with a hyperendemic rate of histoplasmosis (>10 cases/100 patient-years)
* ''[[Pneumocystis jirovecii]]'' (CD4 &lt;200)
** Preferred: [[TMP-SMX]] 1 DS or SS PO daily
** Alternate
*** [[TMP-SMX]] 1 DS PO three times weekly
*** [[Dapsone]] 100 mg PO daily or 50 mg PO BID
*** [[Pentamidine]] nebs 300 mg every month
*** [[Atovaquone]] 1500 mg PO daily
* ''[[Toxoplasma gondii]]'' (CD4 &lt;100 and IgG positive)
** Preferred: [[TMP-SMX]] 1 DS PO daily
** Alternate
*** [[TMP-SMX]] 1 DS PO three times weekly
*** [[TMP-SMX]] 1 SS PO daily
*** [[Dapsone]] 50 mg PO daily + pyrimethamine/leucovorin PO weekly
*** [[Atovaquone]] 1500 mg PO daily
* ''[[Mycobacterium avium complex]]'' (CD4 &lt;50)
** Preferred: [[Azithromycin]] 1200 mg PO once weekly
** Alternate
*** [[Clarithromycin]] 500 mg PO BID
*** [[Azithromycin]] 600 mg PO twice weekly
*** [[Rifabutin]], dose-adjusted to HIV meds
* [[Histoplasma capsulatum]] (CD4 <150 and high risk)
** "High risk" includes occupational exposure or residence in a community with a hyperendemic rate of histoplasmosis (>10 cases/100 patient-years)
** Preferred: [[Itraconazole]] 200 mg PO once daily


== Further Reading ==
== Further Reading ==

Revision as of 01:03, 22 January 2020

CD4 Infections Action
Any Tuberculosis Screen for latent tuberculosis
Vaccinate for pneumococcus, influenza, varicella, HPV (if appropriate), Hepatitis A, and Hepatitis B
<500 Kaposi sarcoma (HHV-8)
Herpes simplex
Varicella zoster
<300 Candida
Molluscum contagiosum
Diarrhea from microsporidia and cryptosporidia
<200 Pneumocystis jirovecii pneumonia Start PJP prophylaxis (Septra SS or DS)
<150 Dimorphic fungi Start histoplasmosis prophylaxis if high risk (occupation or hyperendemic) (itra)
<100 Toxoplasmosis
Cryptococcus
Start toxo prophylaxis if IgG positive (Septra DS)
<50 Mycobacterium avium complex
Cytomegalovirus, including retinitis
Progressive multifocal leukoencephalopathy (PML) from JC virus
Start MAC prophylaxis (azithromycin)

Prophylaxis regimens

Infection Preferred Alternative
Pneumocystis jirovecii (CD4 <200) TMP-SMX 1 DS or SS PO daily TMP-SMX 1 DS PO three times weekly
Dapsone 100 mg PO daily or 50 mg PO BID
Pentamidine nebs 300 mg every month
Atovaquone 1500 mg PO daily
Toxoplasma gondii (CD4 <100 and IgG positive) TMP-SMX 1 DS PO daily TMP-SMX 1 DS PO three times weekly
TMP-SMX 1 SS PO daily
Dapsone 50 mg PO daily + pyrimethamine/leucovorin PO weekly
Atovaquone 1500 mg PO daily
Mycobacterium avium complex (CD4 <50) Azithromycin 1200 mg PO once weekly Clarithromycin 500 mg PO BID
Azithromycin 600 mg PO twice weekly
Rifabutin, dose-adjusted to HIV meds
Histoplasma capsulatum (CD4 <150 and high risk) Itraconazole 200 mg PO once daily

"High risk" for Histoplasma includes occupational exposure or residence in a community with a hyperendemic rate of histoplasmosis (>10 cases/100 patient-years)

Further Reading